Cellectis reports Phase 1 data for leukemia therapy lasme-cel

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. NOW
2. DHR
3. USO
4. NVDA
5. SPY
6. AMD
7. SMCI
8. GOOGL
9. TSLA
10. GM

Go back to Cellectis reports Phase 1 data for leukemia therapy lasme-cel
(NASDAQ: CLLS) Delayed: 2.80 +0.11 (4.09%)
Previous Close $2.69    52 Week High $37.55 
Open $2.80    52 Week Low $16.35 
Day High $2.97    P/E N/A 
Day Low $2.80    EPS $0.00 
Volume 20,698